| Autor: |
Rui, Lu, Zeng-Jun, Li, Gang, An, Shu-Hua, Yi, Wei, Liu, Ting-Yu, Wang, Shu-Hui, Deng, Wei-Wei, Sui, De-Hui, Zou, Lu-Gui, Qiu |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Zhongguo shi yan xue ye xue za zhi. 27(3) |
| ISSN: |
1009-2137 |
| Popis: |
To investigate the clinical characteristics and therapeutic responte of patients with B-CLPD mainly manifested as cytopenia, so as to deeply understand this disease.The clinical data of 13 B-CLPD patients with hematocytopenia as main manifestation, and the absolute count of lymphocytes＜5×10The median age of patients was 59 (43-76) years old, the median of lymphocyte was 1.86 (0.69-4.8) ×10The B-CLPD accompanied with hematocytopenia often displays bone marrow hypohematopoiesis of different degree and easily confuses with the congenital and acquired hemotopoietic faiture diseases. The rituximab treatment may be more appropreate for these patients, but for patients received chemotherapy containing fludarabin, the persistant hematopoietic failure must be especially watched out.以血细胞减少为特征的B-CLPD患者临床分析.探讨以血细胞减少为主要特征的慢性B淋巴增殖性疾病（B-CLPD）患者临床特征及治疗反应，以加深对该类疾病的认识.回顾性分析2003年至2018年我科收治的13例以血细胞减少为主要表现，淋巴细胞绝对值小于5×10患者中位年龄59（43~76）岁，淋巴细胞中位数1.86（0.69~4.8）×10伴有血细胞减少的B-CLPD往往合并不同程度骨髓造血低下,容易与先天性及获得性造血衰竭性疾病混淆。对这类患者在利妥昔单抗治疗或许更为合适，但对联合氟达拉滨的化疗的患者需警惕续持续性造血抑制. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
